NeoStem Inc., of New York, is bringing in gross proceeds of about $16.5 million in a public offering of 13.75 million units – each consisting of one share of common stock and a warrant to purchase 0.75 of a share – priced at $1.20 per unit. Funds will be used for working capital purposes, including R&D work on cell therapeutic product candidates, expansion of business units and other general corporate purposes.